

Phoenix A Ho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8993958/publications.pdf>

Version: 2024-02-01

23
papers

1,584
citations

471509

17
h-index

677142

22
g-index

23
all docs

23
docs citations

23
times ranked

2356
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 623-627.	2.5	23
2	A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. <i>Blood</i> , 2018, 131, 387-396.	1.4	131
3	A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. <i>Blood</i> , 2018, 132, 1125-1133.	1.4	60
4	Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients. <i>Haematologica</i> , 2016, 101, 1343-1350.	3.5	124
5	Sorafenib treatment following hematopoietic stem cell transplant in pediatric <i>FLT3</i> /ITD acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1048-1054.	1.5	58
6	A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of Study ITCC-024 (CPKC412A2114). <i>Blood</i> , 2015, 126, 2564-2564.	1.4	5
7	The prognostic effect of high diagnostic <i>WT1</i> gene expression in pediatric AML depends on <i>WT1</i> SNP rs16754 status: Report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2014, 61, 81-88.	1.5	19
8	High <i>EVI1</i> expression is associated with <i>MLL</i> rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group. <i>British Journal of Haematology</i> , 2013, 162, 670-677.	2.5	35
9	Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. <i>Blood</i> , 2012, 120, 1581-1588.	1.4	256
10	Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. <i>Blood</i> , 2012, 119, 3705-3711.	1.4	91
11	Elevated BAALC Gene Expression Lacks Clinical Significance in Pediatric AML- A Report From the Children's Oncology Group.. <i>Blood</i> , 2012, 120, 2553-2553.	1.4	3
12	High <i>EVI1</i> expression Is Associated with <i>MLL</i> rearrangements and Predicts Decreased Survival in Pediatric AML: A Report From the Children's Oncology Group.. <i>Blood</i> , 2012, 120, 2530-2530.	1.4	0
13	Prognostic implications of the <i>IDH1</i> synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. <i>Blood</i> , 2011, 118, 4561-4566.	1.4	43
14	Leukemic mutations in the methylation-associated genes <i>DNMT3A</i> and <i>IDH2</i> are rare events in pediatric AML: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2011, 57, 204-209.	1.5	109
15	<i>WT1</i> Synonymous Single Nucleotide Polymorphism rs16754 Correlates With Higher mRNA Expression and Predicts Significantly Improved Outcome in Favorable-Risk Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 704-711.	1.6	59
16	Prevalence and prognostic significance of <i>KIT</i> mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. <i>Blood</i> , 2010, 115, 2372-2379.	1.4	156
17	<i>C/EBPβ</i> regulated microRNA-34a targets <i>E2F3</i> during granulopoiesis and is down-regulated in AML with <i>CEBPA</i> mutations. <i>Blood</i> , 2010, 116, 5638-5649.	1.4	119
18	Prevalence and prognostic implications of <i>WT1</i> mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. <i>Blood</i> , 2010, 116, 702-710.	1.4	78

#	ARTICLE	IF	CITATIONS
19	High Expression of the Very Late Antigen-4 Integrin Independently Predicts Reduced Risk of Relapse and Improved Outcome in Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2010, 28, 2831-2838.	1.6	35
20	Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-Based Therapy Allocation In Childhood AML- a Report From the Children's Oncology Group. Blood, 2010, 116, 761-761.	1.4	6
21	TET2 SNP rs2454206 (11762V) Correlates with Improved Survival In Pediatric Acute Myelogenous Leukemia, a Report From the Children's Oncology Group. Blood, 2010, 116, 949-949.	1.4	4
22	Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood, 2009, 113, 6558-6566.	1.4	166
23	Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML A1; Report from Children's Oncology Group. Blood, 2008, 112, 143-143.	1.4	4